Title (en)

METHOD FOR PRODUCING ANTI-HER3 ANTIBODY-DRUG CONJUGATE

Title (de)

VERFAHREN ZUR HERSTELLUNG VON ANTI-HER3-ANTIKÖRPER-ARZNEIMITTEL-KONJUGAT

Title (fr)

PROCÉDÉ DE PRODUCTION DE CONJUGUÉ ANTICORPS-MÉDICAMENT ANTI-HER3

Publication

EP 3789042 A1 20210310 (EN)

Application

EP 20200710 A 20150410

Priority

- JP 2014081454 A 20140410
- EP 15719011 A 20150410
- JP 2015002020 W 20150410

Abstract (en)

Provided is a method for producing an antibody-drug conjugate comprising reacting a compound represented by the following formula: (maleimid-N-yl)-(CH₂)n³-C(=O)-L²-L^P-NH-(CH₂)n¹-L^a-(CH₂)n²-C(=O)-(NH-DX)or (maleimid-N-yl)-(CH₂)n³-C(=O)-L²-L^P-(NH-DX)with an anti-HER3 antibody or a reactive derivative thereof, thus conjugating a drug-linker moiety to the antibody, by forming a thioether bond on a disulfide bond moiety present in a hinge part of the antibody, wherein -(NH-DX) represents a group represented by the following formula:wherein the nitrogen atom of the amino group at position 1 is the connecting position.

IPC 8 full level

A61K 47/68 (2017.01); **A61P 35/00** (2006.01)

CPC (source: CN EP IL KR RU US)

A61K 31/4745 (2013.01 - KR); **A61K 31/535** (2013.01 - RU); **A61K 31/5377** (2013.01 - IL US); **A61K 39/395** (2013.01 - RU); **A61K 39/39558** (2013.01 - CN EP IL US); **A61K 45/06** (2013.01 - CN); **A61K 47/64** (2017.08 - RU); **A61K 47/6803** (2017.08 - IL KR); **A61K 47/68037** (2023.08 - CN EP RU US); **A61K 47/6849** (2017.08 - KR); **A61K 47/6851** (2017.08 - EP IL US); **A61K 47/6855** (2017.08 - EP IL US); **A61K 47/6857** (2017.08 - EP IL US); **A61K 47/6861** (2017.08 - EP IL US); **A61K 47/6863** (2017.08 - EP IL US); **A61K 47/6869** (2017.08 - EP IL US); **A61K 47/6889** (2017.08 - EP IL KR); **A61P 1/02** (2018.01 - EP IL); **A61P 1/04** (2018.01 - EP IL); **A61P 1/16** (2018.01 - EP IL); **A61P 1/18** (2018.01 - EP IL); **A61P 11/00** (2018.01 - EP IL); **A61P 13/02** (2018.01 - EP IL); **A61P 13/08** (2018.01 - EP IL); **A61P 13/10** (2018.01 - EP IL); **A61P 13/12** (2018.01 - EP IL); **A61P 15/00** (2018.01 - EP IL); **A61P 17/00** (2018.01 - EP IL); **A61P 25/00** (2018.01 - EP IL); **A61P 35/00** (2018.01 - EP IL KR RU); **A61P 43/00** (2018.01 - EP IL); **C07K 16/28** (2013.01 - RU); **C07K 16/2863** (2013.01 - CN EP IL US); **C07K 16/30** (2013.01 - CN); **C07K 16/3015** (2013.01 - EP IL US); **C07K 16/3023** (2013.01 - EP IL US); **C07K 16/32** (2013.01 - EP IL KR US); **C07K 16/40** (2013.01 - CN); A61K 2039/505 (2013.01 - EP IL US); A61K 2300/00 (2013.01 - IL); C07K 2317/21 (2013.01 - EP IL US); C07K 2317/24 (2013.01 - EP IL US); C07K 2317/56 (2013.01 - CN); C07K 2317/565 (2013.01 - IL US); C07K 2317/76 (2013.01 - EP IL US); C07K 2317/77 (2013.01 - EP IL US); C07K 2319/00 (2013.01 - CN)

C-Set (source: EP US)

A61K 39/39558 + **A61K 2300/00**

Citation (applicant)

- JP H0559061 A 19930309 - DAIICHI SEIYAKU CO [JP], et al
- JP H08337584 A 19961224 - DAIICHI SEIYAKU CO, et al
- WO 9746260 A1 19971211 - DAIICHI SEIYAKU CO [JP], et al
- WO 0025825 A1 20000511 - DAIICHI SEIYAKU CO [JP], et al
- US 5968511 A 19991019 - AKITA ROBERT [US], et al
- US 5480968 A 19960102 - KRAUS MATTHIAS H [US], et al
- WO 03013602 A1 20030220 - MAX PLANCK GESELLSCHAFT [DE], et al
- WO 2007077028 A2 20070712 - U3 PHARMA AG [DE], et al
- WO 2008100624 A2 20080821 - MERRIMACK PHARMACEUTICALS INC [US], et al
- WO 2012019024 A2 20120209 - IMMUNOGEN INC [US], et al
- WO 9007861 A1 19900726 - PROTEIN DESIGN LABS INC [US]
- WO 9201047 A1 19920123 - CAMBRIDGE ANTIBODY TECH [GB], et al
- WO 9220791 A1 19921126 - CMABRIDGE ANTIBODY TECH [GB], et al
- WO 9306213 A1 19930401 - MEDICAL RES COUNCIL [GB], et al
- WO 9311236 A1 19930610 - MEDICAL RES COUNCIL [GB], et al
- WO 9319172 A1 19930930 - CAMBRIDGE ANTIBODY TECH [GB], et al
- WO 9501438 A1 19950112 - MEDICAL RES COUNCIL [GB], et al
- WO 9515388 A1 19950608 - MEDICAL RES COUNCIL [GB], et al
- WO 9954342 A1 19991028 - UMANA PABLO [CH], et al
- WO 0061739 A1 20001019 - KYOWA HAKKO KOGYO KK [JP], et al
- WO 0231140 A1 20020418 - KYOWA HAKKO KOGYO KK [JP]
- US 4816397 A 19890328 - BOSS MICHAEL A [GB], et al
- US 5916771 A 19990629 - HORI NOBUAKI [JP], et al
- US 6207418 B1 20010327 - HORI NOBUAKI [JP], et al
- US 6207418 B1 20010327 - HORI NOBUAKI [JP], et al
- JP H0687746 A 19940329 - DAIICHI SEIYAKU CO, et al
- JP 2002060351 A 20020226 - DAIICHI SEIYAKU CO
- WO 03038043 A2 20030508 - UAB RESEARCH FOUNDATION [US], et al
- DUCRY, L. ET AL., BIOCONJUGATE CHEM, vol. 21, 2010, pages 5 - 13
- ALLEY, S. C. ET AL., CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 14, 2010, pages 529 - 537
- DAMLE N.K., EXPERT OPIN. BIOL. THER., vol. 4, 2004, pages 1445 - 1452
- SENTER P. D. ET AL., NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 631 - 637
- KUMAZAWA, E.TOHGO, A., EXP. OPIN. INVEST. DRUGS, vol. 7, 1998, pages 625 - 632
- MITSUI, I. ET AL., JPN J. CANCER RES., vol. 86, 1995, pages 776 - 786

- TAKIGUCHI, S. ET AL., JPN J. CANCER RES., vol. 88, 1997, pages 760 - 769
- JOTO, N. ET AL., INT J CANCER, vol. 72, 1997, pages 680 - 686
- KUMAZAWA, E. ET AL., CANCER CHEMOTHER. PHARMACOL., vol. 42, 1998, pages 210 - 220
- DE JAGER, R. ET AL., ANN N Y ACAD SCI, vol. 922, 2000, pages 260 - 273
- INOUE, K. ET AL.: "Polymer Drugs in the Clinical Stage", 2003, pages: 145 - 153
- KUMAZAWA, E. ET AL., CANCER SCI, vol. 95, 2004, pages 168 - 175
- SOEPENBERG, O. ET AL., CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 703 - 711
- WENTE M. N. ET AL., INVESTIGATIONAL NEW DRUGS, vol. 23, 2005, pages 339 - 347
- PLOWMAN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 87, 1990, pages 4905 - 4909
- KRAUS ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 9193 - 9197
- HOLLINGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448
- ALIMANDI ET AL., ONCOGENE, vol. 10, 1995, pages 1813 - 1821
- DEFAZIO ET AL., INT. J. CANCER, vol. 87, 2000, pages 487 - 498
- NADIU ET AL., BR. J. CANCER, vol. 78, 1998, pages 1385 - 1390
- SKERRA, J. MOL. RECOG., 2000
- JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
- RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
- PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
- MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851 - 6855
- TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143
- KUROIWA, Y. ET AL., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448
- YOSHIDA, H. ET AL.: "Animal Cell Technology: Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73
- TOMIZUKA, K. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727
- ANNU. REV. IMMUNOL., vol. 113, 1994, pages 433 - 455
- MUYLDERMANS ET AL., REVIEWS IN MOLECULAR BIOTECHNOLOGY, vol. 74, pages 277 - 302
- HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, pages 484 - 90
- CELL DEATH AND DIFFERENTIATION, vol. 15, 2008, pages 751 - 761
- MOLECULAR BIOLOGY OF THE CELL, vol. 15, December 2004 (2004-12-01), pages 5268 - 5282
- BIO TECHNIQUES, vol. 28, January 2000 (2000-01-01), pages 162 - 165
- KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
- URLAUB, G.CHASIN, L. A., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4126 - 4220
- SAIKI, R. K. ET AL., SCIENCE, vol. 239, 1988, pages 487 - 489
- GLUZMAN, Y., CELL, vol. 23, 1981, pages 175 - 182
- WEIR, D. M.: "Handbook of Experimental Immunology", vol. 1, 2, 3, 1978, BLACKWELL SCIENTIFIC PUBLICATIONS
- KABAT, E. A.MAYER, M. M.: "Experimental Immunochemistry", 1964, CHARLES C THOMAS PUBLISHER
- KOHLER ET AL., EUR. J. IMMUNOL., vol. 6, 1977, pages 511
- MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 495
- PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
- BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164
- WORMSTONE, I. M. ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308
- CARMEN, S. ET AL., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203
- SIRIWARDENA, D. ET AL., OPHTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431
- NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1105 - 1116
- "Proteins, Structures and Molecular Principles", 1984, W. H. FREEMAN AND COMPANY
- THORNTON, NATURE, vol. 354, 1991, pages 105
- ALTSCHUL, STEPHEN F.THOMAS L. MADDENALEJANDRO A. SCHAEFFERJINGHUI ZHANGZHENG ZHANGWEBB MILLERDAVID J. LIPMAN: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402, XP002905950, DOI: 10.1093/nar/25.17.3389
- LORI BURTON, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 12, 2007, pages 265 - 273
- JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134
- ANALYTICAL BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83
- IDUSOGIE ET AL., J IMMUNOL., vol. 166, pages 2571 - 2575
- SHIELDS ET AL., J BIOL CHEM., vol. 276, pages 6591 - 6604
- "A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS, article "Strategies for Protein Purification and Characterization"
- "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
- HERMANSON, G.T: "Bioconjugate Techniques", 1996, ACADEMIC PRESS, pages: 56 - 136,456-493
- PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
- J. ORG. CHEM., vol. 51, 1986, pages 3196

Citation (search report)

- [AD] WO 2012019024 A2 20120209 - IMMUNOGEN INC [US], et al
- [A] WO 2012064733 A2 20120518 - MEDIMMUNE LLC [US], et al
- [YP] WO 2014057687 A1 20140417 - DAIICHI SANKYO CO LTD [JP]
- [YP] WO 2014061277 A1 20140424 - DAIICHI SANKYO CO LTD [JP]

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2015155998 A1 20151015; AU 2015245122 A1 20160818; AU 2015245122 B2 20191024; AU 2020200227 A1 20200206; AU 2020200227 B2 20211007; AU 2021286320 A1 20220120; AU 2021286320 B2 20240418; BR 112016017893 A2 20171017; BR 112016017893 B1 20220823; CA 2939802 A1 20151015; CA 2939802 C 20221101; CN 106163559 A 20161123; CN 106163559 B 20200218; CN 111228511 A 20200605; CN 111228511 B 20240618; CY 1124071 T1 20220527; DK 3129063 T3 20210406; EP 3129063 A1 20170215; EP 3129063 B1 20210127; EP 3789042 A1 20210310; ES 2859648 T3 20211004; HR P20210593 T1 20210514; HU E054411 T2 20210928; IL 248239 A0 20161130; IL 248239 B 20220701; IL 293177 A 20220701; IL 293177 B1 20230301; IL 293177 B2 20230701; IL 300540 A 20230401; IL 300540 B1 20240401; IL 311108 A 20240401; JP 2017197515 A 20171102; JP 2017222638 A 20171221; JP 2017503784 A 20170202; JP 2019135248 A 20190815; JP 2020143114 A 20200910; JP 2021169515 A 20211028; JP 2022180416 A 20221206; JP 2024019172 A 20240208; JP 6105171 B2 20170329; JP 6148422 B1 20170614; JP 6513128 B2 20190515; JP 6707696 B2 20200610; JP 6918182 B2 20210811; JP 7138750 B2 20220916; JP 7383772 B2 20231120; KR 101937549 B1 20190110; KR 102127623 B1 20200629; KR 102186027 B1 20201203; KR 102239413 B1 20210412; KR 102351755 B1 20220114; KR 102399277 B1 20220518; KR 102445502 B1 20220921; KR 102495426 B1 20230206; KR 102624244 B1 20240111; KR 20160144396 A 20161216; KR 20190004837 A 20190114; KR 20200077620 A 20200630; KR 20200136052 A 20201204;

KR 20210041126 A 20210414; KR 20210115056 A 20210924; KR 20220012402 A 20220203; KR 20220068270 A 20220525; KR 20220132025 A 20220929; KR 20230021173 A 20230213; KR 20240008415 A 20240118; LT 3129063 T 20210625; MX 2016010533 A 20161212; MX 2021004884 A 20210615; MY 195180 A 20230111; NZ 722668 A 20240223; PH 12016501711 A1 20161219; PL 3129063 T3 20210712; PT 3129063 T 20210401; RS 61711 B1 20210531; RU 2016143351 A 20180515; RU 2016143351 A3 20190305; RU 2019143766 A 20200220; RU 2711640 C2 20200117; SG 10201907807X A 20190927; SG 11201608309P A 20161129; SI 3129063 T1 20210831; TW 201542230 A 20151116; TW 202108176 A 20210301; TW 202218685 A 20220516; TW I704928 B 20200921; TW I745021 B 20211101; TW I826828 B 20231221; US 10383878 B2 20190820; US 11298359 B2 20220412; US 2017021031 A1 20170126; US 2019151328 A1 20190523

DOCDB simple family (application)

JP 2015002020 W 20150410; AU 2015245122 A 20150410; AU 2020200227 A 20200113; AU 2021286320 A 20211215; BR 112016017893 A 20150410; CA 2939802 A 20150410; CN 201580019138 A 20150410; CN 202010034933 A 20150410; CY 211100356 T 20210426; DK 15719011 T 20150410; EP 15719011 A 20150410; EP 20200710 A 20150410; ES 15719011 T 20150410; HR P20210593 T 20210413; HU E15719011 A 20150410; IL 24823916 A 20161006; IL 29317722 A 20220519; IL 30054023 A 20230209; IL 31110824 A 20240226; JP 2016540705 A 20150410; JP 2017037872 A 20170301; JP 2017098589 A 20170518; JP 2019073941 A 20190409; JP 2020087844 A 20200520; JP 2021119487 A 20210720; JP 2022141262 A 20220906; JP 2023190804 A 20231108; KR 20167029685 A 20150410; KR 20197000169 A 20150410; KR 20207018066 A 20150410; KR 20207033997 A 20150410; KR 20217010205 A 20150410; KR 20217028736 A 20150410; KR 20227001001 A 20150410; KR 20227016151 A 20150410; KR 20227031970 A 20150410; KR 20237003389 A 20150410; KR 20247000775 A 20150410; LT 15719011 T 20150410; MX 2016010533 A 20150410; MX 2021004884 A 20160812; MY PI2016001655 A 20150410; NZ 72266815 A 20150410; PH 12016501711 A 20160830; PL 15719011 T 20150410; PT 15719011 T 20150410; RS P20210435 A 20150410; RU 2016143351 A 20150410; RU 2019143766 A 20150410; SG 10201907807X A 20150410; SG 11201608309P A 20150410; SI 201531545 T 20150410; TW 104111534 A 20150410; TW 109127496 A 20150410; TW 110135505 A 20150410; US 201615285156 A 20161004; US 201916264395 A 20190131